A A A
Onderzoek Publicaties 2009

2009

INTERNATIONALE WETENSCHAPPELIJKE PUBLICATIES (peer reviewed):

  • Baars MAE, van Boxtel MPJ, Dijkstra JB, Visser PJ, van den Akker M, Verhey FRJ, Jolles J. Predictive value of mild cognitive impairment for dementia. the influence of case definition and age.  Dement Geriatr Cogn Disord 2009;27:173-181.
  • Barnes J, Ourselin S, Fox NC. Clinical application of measurement of hippocampal atrophy in degenerative dementias.  Hippocampus 2009;19:510-516.
  • Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C, Thompson P, Fox NC. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 2009;30:1711-1723.
  • Benisty S, Gouw AA, Porcher R, Madureira S, Hernandez K, Poggesi A, van der Flier WM, van Straaten ECW, Verdelho A, Ferro J, Pantoni L, Inzitari D, Barkhof F, Fazekas F, Chabriat H, on  behalf of the LADIS study. Location of lacunar infarcts correlates with cognition in a sample of non disabled subjects with age-related white matter changes: the LADIS study.  J Neurol Neurosurg Psychiatry 2009;80:478-483.
  • Bierman EJM, Comijs HC, Jonker C, Scheltens P, Beekman ATF. The effect of anxiety and depression on decline of memory function in Alzheimer's disease. Int Psychogeriatr 2009;21:1142-1147.
  • Blahak C, Baezner H, Pantoni L, Poggesi A, Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Langhorne P, O'Brien J, Visser MC, Wahlund L-O, Waldemar G, Wallin A, Inzitari D, Hennerici MG on behalf of the LADIS study group. Deep frontal and periventricular age-related white matter changes but not basal ganglia and infratentorial hyperintensities are associated with falls - cross-sectional results from the LADIS study.  J Neurol Neurosurg Psychiatry 2009;80:608-613.
  • Bouwman FH, Schoonenboom NSM, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 2009;30:1895-1901.
  • Chan D, Anderson V, Pijnenburg Y, Whitwell J, Barnes J, Scahill R, Stevens JM, Barkhof F, Scheltens P, Rossor MN, Fox NC.The clinical profile of right temporal lobe atrophy.  Brain 2009;132:1287-1298.
  • Chupin M, Gérardin E, Cuingnet R, Boutet C, Lemieux L, Lehéricy S, Benali H, Garnero L, Colliot O, and the Alzheimer's Disease Neuroimaging Initiative(waaronder Fox NC). Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. Hippocampus 2009;19:579-587.
  • Clarkson MJ, Ourselin S, Nielsen C, Leung KK, Barnes J, Whitwell JL, Gunter JL, Hill DLG, Weiner MW, Jack CR Jr, Fox NC. and the Alzheimer’s Disease Neuroimaging Initiative. Comparison of phantom and registration scaling corrections using the ADNI cohort.  Neuroimage 2009;47:1506-1513.
  • Damoiseaux JS, Smith SM, Witter MP, Sanz-Arigita EJ, Barkhof F, Scheltens P, Stam CJ, Zarei M, Rombouts SARB. White matter tract integrity in aging and Alzheimer's disease. Hum Brain Mapp 2009;30:1051-1059.
  • Delaloye C, de Bilbao F, Moy G, Baudois S, Weber K, Campos L, Canuto A, Giardini U, von Gunten A, Stancu RI, Scheltens P, Lazeyras F, Millet P, Giannakopoulos P, Gold G. Neuroanatomical and neuropsychological features of euthymic patients with bipolar disorder. Am J Geriatr Psychiatry 2009;17: 1012-1021.
  • van Es ACGM, van der Flier WM, Box FMA, Middelkoop HAM, Westendorp RGJ, van Buchem MA, van der Grond J. Carotid and basilar artery wall shear stress in Alzheimer's disease and mild cognitive impairment.  Dement Geriatr Cogn Disord 2009;28:220-224.
  • van Exel E, Eikelenboom P, Comijs H, Frölich M, Smit JH, Stek ML, Scheltens P, Eefsting JE, Westendorp RGJ. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch Gen Psychiatry 2009;66:1263-1270.
  • van der Flier WM, Scheltens P. Alzheimer disease: Hippocampal volume loss andAlzheimer disease progression.  Nat Rev Neurol 2009;5:361-362.
  • van der Flier WM, Scheltens P. Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data.  J Nutr Health Aging 2009;13:353-355.
  • Fox NC, Kennedy J. Structural imaging markers for therapeutic trials in Alzheimer's disease.  J Nutr Health Aging 2009;13:350-352.
  • Gauthier S, Scheltens P. Can we do better in developing new drugs for Alzheimer's disease? Alzheimers Dement 2009;5:489-491.
  • Gómez C, Stam CJ, Hornero R, Fernández A, Maestú F. Disturbed beta band functional connectivity in patients with mild cognitive impairment: a MEG Study.  IEEE Trans Biomed Eng 2009;56:1683-1690.
  • Goos JDC, Kester MI, Barkhof F, Klein M, Blankenstein MA, Scheltens P, van der Flier WM.  Patients with Alzheimer disease with multiple microbleeds. Relation with cerebrospinal fluid biomarkers and cognition.  Stroke 2009;40:3455-3460.
  • Gutiérrez-Galve L, Lehmann M, Hobbs NZ, Clarkson MJ, Ridgway GR, Crutch S, Ourselin S, Schott JM, Fox NC, Barnes J. Patterns of cortical thickness according to APOE genotype in Alzheimer's disease. Dement Geriatr Cogn Disord 2009;28:476-485.
  • de Haan W, Pijnenburg YAL, Strijers RLM, van der Made Y, van der Flier WM, Scheltens P, Stam CJ. Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. BMC Neurosci 2009;10/101:1-12.
  • Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann H-E, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088-1093.
    Erratum: Nat Genet 2009;41:1156.
  • Henley SMD, Wild EJ, Hobbs NZ, Scahill RI, Ridgway GR, MacManus DG, Barker RA, Fox NC, Tabrizi SJ. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease.  J Neurol 2009;256:203-212.
  • Henley SMD, Wild EJ, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord 2009;24:932-936.
  • Henneman WJP, Vrenken H, Barnes J, Sluimer JC, Verwey NA, Blankenstein MA, Klein M, Fox NC, Scheltens P, Barkhof F, van der Flier WM. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease.  Neurology 2009;73:935-940.
  • Henneman WJP, Sluimer JD, Cordonnier C, Baak MME, Scheltens P, Barkhof F, van der Flier WM.  MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population. Stroke 2009;40:492-498.
  • Henneman WJP, Sluimer JD, Barnes J, van der Flier WM, Sluimer IC, Fox NC, Scheltens P, Vrenken H, Barkhof F. Hippocampal atrophy rates in Alzheimer disease: Added value over whole brain volume measures. Neurology 2009;72:999-1007.
  • Hobbs NZ, Henley SMD, Wild EJ, Leung KK, Frost C, Barker RA, Scahill RI, Barnes J, Tabrizi SJ, Fox NC. Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease.  Neuroimage 2009;47:1659-1665.
  • Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM, and the Alzheimer's Disease Neuroimaging Initiative.( waaronder o.a. Fox N.)Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106:20954-20959.
  • Hu K, van Someren EJW, Shea SA, Scheer FAJL. Reduction of scale invariance of activity fluctuations with aging and Alzheimer's disease: Involvement of the circadian pacemaker.  Proc Natl Acad Sci U S A 2009;106:2490-2494.
  • Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, Langhorne P, O'Brien J, Scheltens P, Visser MC, Wahlund LO, Waldemar G, Wallin A, Pantoni L, on behalf  of the LADIS Study Group. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ 2009;339:b2477.
  • Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC and the Alzheimer's Disease Neuroimaging Initiative. (waaronder Fox N). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.  Brain 2009;132:1355-1365.
  • Jokinen H, Kalska H, Ylikoski R, Madureira S, Verdelho A, van der Flier WM, Scheltens P, Barkhof F, Visser MC, Fazekas F, Schmidt R, O'Brien J, Waldemar G, Wallin A, Chabriat H, Pantoni L,Inzitari D, Erkinjuntti T, on behalf of the LADIS group. Longitudinal cognitive decline in subcortical ischemic vascular disease - The LADIS Study. Cerebrovasc Dis 2009;27:384-391.
  • Jokinen H, Kalska H, Ylikoski R, Madureira S, Verdelho A, Gouw A, Scheltens P, Barkhof F, Visser MC, Fazekas F, Schmidt R, O'Brien J, Hennerici M, Baezner H, Waldemar G, Wallin A, Chabriat H, Pantoni L, Inzitari D, Erkinjuntti T. MRI-defined subcortical ischemic vascular disease: baseline clinical and neuropsychological findings. Cerebrovasc Dis 2009;27:336-344.
  • Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. J Alzheimers Dis 2009;16:601-617.
  • Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YAL, van Elk EJ, Scheltens P, van der Flier WM. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009;73:1353-1358.
  • Kester MI, Scheltens P. Dementia: the bare essentials. Pract Neurol 2009;9:241-251.
  • Klöppel S, Stonnington CM, Chu C, Draganski B, Scahill RI, Rohrer JD, Fox NC, Ashburner J, Frackowiak RSJ. A plea for confidence intervals and consideration of generalizability in diagnostic studies. Brain 2009;132:e102,1-3.
  • Knight WD, Ahsan RL, Jackson J, Cipolotti L, Warrington EK, Fox NC, Rossor MN. Pure progressive amnesia and the APPV717G mutation. 
    Alzheimer Dis Assoc Disord 2009;23:410-414.
  • Liedorp M, van der Flier WM, Hoogervorst ELJ, Scheltens P, Stam CJ. Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort. Dement Geriatr Cogn Disord 2009;27:18-23.
  • Lloyd SE, Rossor M, Fox N, Mead S, Collinge J. HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q.  BMC Med Genet 2009;10:Art no. 90.
  • Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. 
    JAMA 2009;302:385-393.
  • Meeuwsen EJ, Melis RJF, Adang EM, Golüke Willemse GA, Krabbe PF, de Leest BJ, van Raak FHJM, Schölzel Dorenbos CJM, Visser MC, Wolfs CA, Vliek S, Olde Rikkert MGM. Cost-effectiveness of post-diagnosis treatment in dementia coordinated by multidisciplinary memory clinics in comparison to treatment coordinated by general practioners: an example of a pragmatic trial. J Nutr Health Aging 2009;13:242-248.
  • Montez T, Poil SS, Jones BF, Manshanden I, Verbunt JPA, van Dijk BW, Brussaard AB, van Ooyen A, Stam CJ, Scheltens Ph, Linkenkaer-Hansen K. Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease.  Proc Natl Acad Sci U S A 2009;106:1614-1619.
  • Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ and the Alzheimer's Disease Neuroimaging Initiative (waaronder Fox N). Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132:1310-1323.
  • Mourik JEM, Lubberink M, Schuitemaker A, Tolboom N, van Berckel BNM, Lammertsma AA, Boellaard R. Image-derived input functions for PET brain studies. Eur J Nucl Med Mol Imaging 2009;36:463-471.
  • Mulder SD, Heijst JA, Mulder C, Martens F, Hack CE, Scheltens P, Blankenstein MA, Veerhuis R. CSF levels of PSA and PSA-ACT complexes in Alzheimer's disease.  Ann Clin Biochem 2009;46:477-483.
  • Nobili F, De Carli F, Frisoni GB, Portet F, Verhey F, Rodriguez G, Caroli A, Touchon J, Morbelli S, Guerra UP, Dessi B, Brugnolo A, Visser PJ. SPECT predictors of cognitive decline and Alzheimer's disease in mild cognitive impairment. J Alzheimers Dis 2009;17:761-772.
  • Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ.
    Conversion of amyloid positive and negative MCI to AD over 3 years. An 11C-PIB PET study. Neurology 2009;73:754-760.
  • Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, Walker Z, Kennedy A, Fox N, Rossor M, Brooks DJ. Microglial activation and amyloid deposition in mild cognitive impairment: A PET study.  Neurology 2009 72: 56-62.
  • Omar R, Sampson EL, Loy CT, Mummery CJ, Fox NC, Rossor MN, Warren JD. Delusions in frontotemporal lobar degeneration.  J Neurol 2009;256:600-607.
  • Oosterman JM, van Someren EJW, Vogels RLC, van Harten B, Scherder EJA. Fragmentation of the rest-activity rhythm correlates with age-related cognitive deficits.  J Sleep Res 2009;18:129-135.
  • van de Pol LA, Verhey F, Frisoni GB, Tsolaki M, Papapostoulou P, Nobili F, Wahlund L-O, Minthon L, Frölich L, Hampel H, Soininen H, Knol DL, Barkhof F, Scheltens P, Visser PJ. White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. J Neurol Neurosurg Psychiatry 2009;80:1069-1074.
  • Ramakers IHGB, Visser PJ, Bittermann AJN, Ponds RWHM, van Boxtel MPJ, Verhey FR. Characteristics of help-seeking behaviour in subjects with subjective memory complaints at a memory clinic: a case-control study. Int J Geriatr Psychiatry 2009;24:190-196.
  • Reesink F, Boelaarts L, Weinstein HC. Zelfverwaarlozing bij ouderen, een complex probleem. Ned Tijdschr Geneeskd 2009;153:1218-1221.
  • Richard E, Kuiper R, Dijkgraaf MGW, van Gool WA, for the Evaluation of Vascular care in Alzheimer’s disease Study Group ( waaronder: Scheltens P).Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc 2009;57:797-805.
  • Ridgway GR, Omar R, Ourselin S, Hill DLG, Warren JD, Fox NC. Issues with threshold masking in voxel-based morphometry of atrophied brains. Neuroimage 2009;44:99-111.
  • Riemersma- van der Lek RF, Swab DF, Twisk J, Hol EM, Hoogendijk WJG, van Someren E. Melatonin in elderly patients. Biol Rhythm Res 2009;40:83-84.
  • Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, Isaacs AM, Authier A, Ferrari R, Fox NC, Mackenzie IR, Warren JD, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN. The heritability and genetics of frontotemporal lobar degeneration. Neurology 2009;73:1451-1456.
  • Rohrer JD, Warren JD, Modat M, Ridgway GR, Douiri A, Rossor MN, Ourselin S, Fox NC. Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology 2009;72:1562-1569.
  • Rohrer JD, Ahsan RL, Isaacs AM, Nielsen JE, Ostergaard L, Scahill R, Warren JD, Rossor MN, Fox NC, Johannsen P, the FReJA consortium. Presymptomatic generalized brain atrophy in frontotemporal dementia caused by CHMP2B mutation. Dement Geriatr Cogn Disord 2009;27:182-186.
  • Rombouts SARB, Damoiseaux JS, Goekoop R, Barkhof F, Scheltens P, Smith SM, Beckmann CF. Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum Brain Mapp 2009;30:256-266.
  • Ropele S, Seewann A, Gouw AA, van der Flier WM, Schmidt R, Pantoni L, Inzitari D, Erkinjuntti T, Scheltens P, Wahlund LO, Waldemar G, Chabriat H, Ferro J, Hennerici M, O'Brien J, Wallin A, Langhorne P, Visser MC, Barkhof F, Fazekas F; on behalf of the LADIS study group. Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: The LADIS (Leukoaraiosis and Disability in the elderly) study.  J Magn Reson Imaging 2009;29:268-274.
  • Ryan NS, Fox NC. Alzheimer disease: visual rating of atrophy aids diagnostic accuracy. Nat Rev Neurol 2009;5:243-244.
  • Ryan NS, Fox NC.Imaging biomarkers in Alzheimer's disease. Ann N Y Acad Sci 2009;1180:20-27.
  • Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, for the Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73: 2061-2070.
  • Scheltens P. Imaging in Alzheimer's disease. Dialogues Clin Neurosci 2009;11:191-199.
  • Scheltens P. Moving forward with nutrition in Alzheimer’s disease. Eur J Neurol 2009;16(suppl.1):19-22.
  • Scheltens P. Nutrition and dementia.  Eur J Neurol 2009;16(suppl.1):III-IV.
  • Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NSM, Hack CE, Blankenstein MA, Jonker C.Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 2009;30:1885-1889.
  • Sikkes SAM, de Lange-de Klerk ESM, Pijnenburg YAL, Scheltens P, Uitdehaag BMJ. A systematic review of Instrumental Activities of Daily Living scales in dementia: room for improvement.  J Neurol Neurosurg Psychiatry 2009;80:7-12.
  • Sluimer JD, van der Flier WM, Karas GB, van Schijndel R, Barnes J, Boyes RG, Cover KS, Olabarriaga SD, Fox NC, Scheltens P, Vrenken H, Barkhof F. Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. Eur Radiol 2009;19:2826-2833.
  • Staekenborg SS, Koedam ELGE, Henneman WJP, Stokman P, Barkhof F, Scheltens P, van der Flier WM. Progression of mild cognitive impairment to dementia. Contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke 2009;40:1269-1274.
  • Stam CJ, de Haan W, Daffertshofer A, Jones BF, Manshanden I, van Cappellen van Walsum AM, Montez T, Verbunt JPA, de Munck JC, van Dijk BW, Berendse HW, Scheltens P. Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain 2009;132:213-224.
  • Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RAC, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC; the TRACK-HD investigators. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
  • Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, Barkhof F, Scheltens P, Lammertsma AA, van Berckel BN. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med 2009;50:191-197.
  • Tolboom N, van der Flier WM, Yaqub M, Koene T, Boellaard R, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BNM.   Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology 2009;73:2079-2085.
  • Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BNM. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP Binding.  J Nucl Med 2009;50:1464-1470.
  • Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BNM. Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009;36:1629-1638.
  • Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M; for the AN1792 (QS-21)-251 Study Team. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6:144-151.
  • Verwey NA, Veerhuis R, Twaalfhoven HAM, Wouters D, Hoozemans JJM, Bollen YJM, Killestein J, Bibl M, Wiltfang J, Hack CE, Scheltens P, Blankenstein MA. Quantification of amyloid beta 40 in cerebrospinal fluid.  J Immunol Methods 2009;348:57-66.
  • Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, van Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease.  Ann Clin Biochem 2009;46:235-240.
  • Visser PJ, Knopman DS. Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI.  Neurology  2009;73:744-745.
  • Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund L-O, Freund-Levi Y,Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H,  Olde Rikkert M, Verbeek MM, Spiru L, Blennow K. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.  Lancet Neurol 2009;8:619-627.
  • Visser PJ. Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment. J Nutr Health Aging 2009;13:344-345.
  • van der Vlies AE, Verwey NA, Bouwman FH,. Blankenstein MA, Klein M, Scheltens P, van der Flier WM. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009;72:1056-1061.
  • van der Vlies AE, Koedam ELGE, Pijnenburg YAL, Twisk JWR, Scheltens P, van der Flier WM. Most rapid cognitive decline in APOE ε4 negative Alzheimer's disease with early onset. Psychol Med 2009;39:1907-1911.
  • van Vliet P, Westendorp RGJ, Eikelenboom P, Comijs HC, Frölich M, Bakker E, van der Flier W, van Exel E. Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels. Neurology 2009;73:681-687.
  • Wattjes MP, Henneman WJP, van der Flier WM, de Vries O, Träber F, Geurts JJG, Scheltens P, Vrenken H, Barkhof F. Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT.  Radiology 2009;253:174-183.
  • Wild EJ, Fox NC. Serial volumetric MRI in Parkinsonian disorders. Mov Disord. 2009;24(Suppl. 2):S691-S698.
  • Yaqub M, Boellaard R, van Berckel BNM, Tolboom N, Luurtsema G, Dijkstra AA, Lubberink M, Windhorst AD, Scheltens P, Lammertsma AA. Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies.  Mol Imaging Biol 2009;11:322-333.
  • Yaqub M, Tolboom N, van Berckel BNM, Scheltens P, Lammertsma AA, Boellaard R. Simplified parametric methods for [18F]FDDNP studies. Neuroimage 2009;49:433-441.
  • Zarei M, Damoiseaux JS, Morgese C, Beckmann CF, Smith SM, Matthews PM, Scheltens P, Rombouts SARB, Barkhof F. Regional white matter integrity differentiates between vascular dementia and Alzheimer disease. Stroke 2009;40:773-779.
  • Davies RJ, Nugent CD, Donnelly M, Hettinga M, Meiland F, Moelaert F, Mulvenna MD, Bengtsson JE, Craig D, Dröes, RM A User-Driven Approach to Develop a Cognitive Prosthetic to Address Unmet Needs of People with Mild Dementia. Journal of Pervasive and Mobile Computing, 2009;5(3):253-267.
  • Roest HG van der, Meiland FJM, Comijs HC, Derksen E, Jansen A, Hout H. van, Jonker C, Dröes RM. What do community dwelling people with dementia need? A survey among those who are known by care and welfare services. International Psychogeriatrics 2009 Oct;21(5):949-65.

Boek(hoofdstukken) en vakpublicaties:

  • Blankenstein MA, Verwey NA, Mulder C, Kester MI, van der Flier WM, Veerhuis R, Teunissen CE, Scheltens P. Biochemical markers for Alzheimer’s disease in cerebrospinal fluid. Clinical Laboratory International 2009;33(4):17-19.
  • van der Flier WM, Scheltens Ph. Huwelijk beschermt tegen dementie. Ned Tijdschr Geneeskd 2009;153:A1059.
  • van der Flier WM, Staekenborg SS, Barkhof F, Scheltens Ph. Structural neuroimaging: CT and MRI. In: Wahlund L-O, Erkinjuntti T, Gauthier S (eds), Vascular cognitive impairment in clinical practice. New York etc., Cambridge University Press, 2009:58-69.
  • Lemstra AW. Proefschriftbespreking: De rol van het cholinerge systeem en inflammatie bij cognitieve acteruitgang. Tschr Neurol Neurochir 2009;110:108-110.
  • Liedorp M, Stam CJ. Elektro-encefalogram (EEG). In: Jonker C, Slaets JPJ, Verhey FRJ (red), Handboek dementie; laatste inzichten in diagnostiek en behandeling. Houten, Bohn  Stafleu van Loghum 2009:53-58.
  • Pijnenburg YAL. Boekbespreking: Autisme en aspergersyndroom. Tijdschr Neuropsychiatrie & Gedragsneurologie 2009;8:158.
  • Pijnenburg YAL.  Het dementieconcept. Tijdschr Neuropsychiatrie & Gedragsneurologie 2009;8:238.
  • Pijnenburg YAL. Commentaar: Oorzaken van dementie op zeer jinge leeftijd. HealthDirect Neurologie 2009;5(2):20.
  • Pijnenburg YAL, Kerssens CJ, Sanders J. De psychiatrische differentiaaldiagnose van FTD. Tijdschr Neuropsychiatrie & Gedragsneurologie 2009;8:153-157.
  • Pijnenburg YAL. Twee werelden. Tijdschr Neuropsychiatrie & Gedragsneurologie 2009;8:86.
  • Rövekamp FA, Visser MC, Wattjes MP, Pijnenburg YAL. Neuro-imaging. Uw diagnose? Tijdschr Neurol Neurochir 2009;110:312-313.
  • Scheltens P. Dementie: plaques aantonen. In Bär D, et al. (red.), Brein in beeld, beeldvorming bij hersenonderzoek. Den Haag, Stichting Bio-Wetenschappen en Maatschappij, 2009:60-63.
  • Scheltens Ph, van der Flier WM, Rozemuller AM, Pijnenburg YAL. Ziekte van Alzheimer. In: Jonker C, Slaets JPJ, Verhey FRJ (red), Handboek dementie; laatste inzichten in diagnostiek en behandeling. Houten, Bohn  Stafleu van Loghum 2009:197-209.
  • Seelaar H, Pijnenburg YAL, van Swieten JC. Frontotemporale dementie (FTD). In: Jonker C, Slaets JPJ, Verhey FRJ (red), Handboek dementie; laatste inzichten in diagnostiek en behandeling. Houten, Bohn  Stafleu van Loghum 2009:211-218.
  • Smits LL, Koene T, Pijnenburg YAL, Scheltens Ph, van der Flier WM. De kloktekentest: bepreking van de  literatuur en voorbeelden uit de praktijk. Tijdschr Neuropsychologie 2009;(nr. 3):2-14.
  • Verhey FRJ, Pijnenburg YAL. Klinische diagnostiek. In: Jonker C, Slaets JPJ, Verhey FRJ (red), Handboek dementie; laatste inzichten in diagnostiek en behandeling. Houten, Bohn  Stafleu van Loghum 2009:25-32.
  • Verwey NA.  Een heldere kijk op dementie; toekomstige ontwikkeling en inzet van biomarkers voor dementie. Health Management Forum 2009;3:28-29
  • Verwey NA,  Scheltens Ph. Voorspellen van de ziekte van Alzheimer met liquor biomarkers. Ned Tijdschr Geneeskd 2009;153:A1058.
  • Visser PJ. Mild cognitive impairment. In: Jonker C, Slaets JPJ, Verhey FRJ (red), Handboek dementie; laatste inzichten in diagnostiek en behandeling. Houten, Bohn  Stafleu van Loghum 2009:187-195.
  • Bentvelzen S, Meiland F,  Bouman A, Dröes RM. Het Europese COGKNOW-project: Een elektronische assistent voor mensen met dementie. Denkbeeld, Tijdschrift voor Psychogeriatrie 2009;6:6-9.
  • Bouman A, Meiland F, Dröes RM, Sävenstedt S, Moelaert F, Mulvenna M, Craig D, Bengtsson JE, Nugent C. COGKNOW: Development of a Cognitive Prosthetic for People with Mild Dementia Living at Home. IPA Bulletin 2009;26 (2).
  • De Kinderen S, Gordijn J, Dröes RM, Meiland F. A computational approach towards eliciting needs-driven bundles of healthcare services. Conference proceedings 22nd Bled eConference eEnablement: Facilitating an Open, Effective and Representative eSociety, June 14-17, 2009, Bled, Slovenia, pp. 220-236.
  • Meiland F, Roest HG van der, Dröes RM. Electronisch informatiesysteem: de DementieWijzer. Zonnehuis Magazine, okt. 2009;4:10-11.

Dissertaties:

  • Gouw AA. Cerebral small vessel disease on MRI: clinical impact and underlying pathology. Enschede, Ipskamp Drukkers, 2009. 188 pp. Proefschrift Amsterdam V.U. Promotoren: Ph Scheltens, F Barkhof, Copromotor: WM van der Flier
  • Henneman WJP. Advances in hipocampal atrophy measurement in dementia: beyond diagnostics. Enschede, Ipskamp Drukkers, 2009. 166 pp. Proefschrift Amsterdam V.U. Promotoren: F Barkhof,  Ph Scheltens, Copromotoren: WM van der Flier,  H. Vrenken
  • Mulder C. Biomarkers in Alzheimer’s disease. Enschede, Ipskamp Drukkers, 2009. 180 pp. Proefschrift Amsterdam V.U. Promotoren: MA Blankenstein, Ph Scheltens
  • van der Roest HG. Care needs in dementia and digital interactive information provisioning. Enschede, Ipskamp Drukkers, 2009. 254 pp. Proefschrift Amsterdam V.U. Promotoren: RM Dröes, C. Jonker, Copromotoren: FJM Meiland, P Scheltens
  • Staekenborg SS. From normal aging to dementie: risk factors & clinical findings in relation to vascular changes on brain MRI. Z Pl., Z.Uitg, 2009. 180 pp. Proefschrift Amsterdam V.U. Promotoren:Ph Scheltens, F. Barkhof; Copromotor:WM van der Flier
Login naar de portal Stel een vraag Doneren

Onderzoek

Privacy | Disclaimer | © COZ Marketing 2010